+44 20 8123 2220
info@marketpublishers.com

Investigation Report on China Adalimumab Market, 2010-2018

https://marketpublishers.com/r/IA0609103CDEN.html
Date: March 2014
Pages: 40
Price: US$ 1,800.00 (Single User License)
ID: IA0609103CDEN

Abstracts

Adalimumab is a TNF (tumor necrosis factor) inhibiting anti-inflammatory drug, the first fully human monoclonal antibody drug approved by the FDA. It was discovered through collaboration between BASF Bioresearch Corporation and Cambridge Antibody Technology in 1993, then further manufactured at BASF Bioresearch Corporation and developed by BASF Knoll (BASF Pharma) and, ultimately, manufactured and marketed by Abbott Laboratories after the acquisition of BASF Pharma by Abbott. In 2000 Abbott Laboratories took over Knoll with USD 6.9 billion. At the end of 2002 adalimumab was approved to the market by FDA.

As of 2008 adalimumab (produced by Abbott with the trade name "Humira") had been approved by FDA for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, moderate to severe chronic psoriasis and juvenile idiopathic arthritis. Adalimumab is the best seller in the world in recent years. It can satisfy many urgent clinical needs because of its wide range of indications. The global sales revenue of Humira in 2012 exceeded USD 9 billion, and it reached USD 10 billion in 2013. Humira was launched in China in August 2010. According to CRI's market investigation, the sales revenue of adalimumab in Chinese sample hospitals grew 20 times from 2010 to 2013. More than 10 million people in China have adalimumab indications.

Humira is expected to bring Abbott (now AbbVie) the total sales revenue of USD 100 billion before its patent expires in 2016. This has made Humira the primary target of pharmaceutical enterprises from the world. More than 20 enterprises worldwide are developing adalimumab generic drugs and many of them are Chinese enterprises.

Huahai Pharmaceutical announced in May 2013 that they signed a strategic alliance

+44 20 8123 2220
info@marketpublishers.com

agreement with ONCOBIOLOGICS to jointly develop biological drugs. The agreement states that Huahai Pharmaceutical is bestowed with 100% marketing right of four monoclonal antibody biological drugs in China. If Huahai Pharmaceutical establishes joint ventures in the U.S. to develop the four monoclonal antibody biological drugs, it will have 51% of the marketing right in developed countries such as the U.S. and Europe. Meanwhile the company will jointly establish a biopharmaceutical company with ONCOBIOLOGICS in China to develop monoclonal antibody biological drugs and conduct industrialization technique application research.

In December 2013 Huahai was informed by Oncobiologics that the MAb biosimilar Humira® jointly developed was approved to launch phase I clinical trial by EMA (the European Medicines Agency) and FDA.

Duo to large market size, challenging R&D and high profit of the monoclonal antibody drug market, the collaboration between Huahai Pharmaceutical and Oncobiologics is praised by the industry as the "Second Transformation" supported by the international biopharmaceutical giant's strong R&D strength. The approval for adalimumab to launch phase I clinical trial means a significant progress of the collaboration.

However, follow-up R&D of the monoclonal antibody product requires a large amount of time before the product appears on the market. It is estimated that Abbott will continue to occupy the global market of adalimumab in the next few years. However, the situation will change gradually after 2017.

Through this report, the readers can acquire the following information:

Market Size of Adalimumab in China

Sales price of Adalimumab in Hospital Market in China

Price of Adalimumab Produced by Vetter Pharma Fertigung GmbH & Co. KG in China Hospital, 2014

Manufacturing Schedule of Adalimumab Generic Drug

Prospect of China Adalimumab Market

The following enterprises and people are recommended to purchase this report:

+44 20 8123 2220
info@marketpublishers.com

Manufacturers of Crude and Finished Monoclonal Antibody Remedy

Medical Institutions

Investors/Research Institutes Focusing on Monoclonal Antibody Market

+44 20 8123 2220
info@marketpublishers.com

Contents

+44 20 8123 2220
info@marketpublishers.com

Selected Charts

SELECTED CHARTS

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Investigation Report on China Adalimumab Market, 2010-2018
Product link: https://marketpublishers.com/r/IA0609103CDEN.html
Price: US$ 1,800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/IA0609103CDEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970